

	RA	Other joint diseases
Number of samples/patients	11/11	15/13
Female sex	82%	54%
Mean age	66	55
Percent RF positive (serum)	55%	7%
Percent ACPA positive (serum)	73%	7%
Patients with erosive course of disease	9	3
Patients on corticosteroids	6	7
Patients on DMARDs	1	7
Patients on Biologicals	4	4
Patients on JAK inhibitors	0	0
Patients on immune checkpoint inhibitors	0	1
Mean synovial cell number [cells/nl]	7,56	4,01
Presence of crystals in SF sample	0	1
Presence of bacteria/fungi in SF sample	0	0

Suppl. Table 1. Summary of characteristics of the patients whose synovial fluid samples were analyzed. The table refers to figure 3. Values represent absolute numbers. Abbreviations: DMARDs=disease-modifying anti-rheumatic drugs, JAK=janus kinase, SF=synovial fluid

<i>CDI6 Activation Index</i>	Age	Gender	RF (IU/ml)	ACPA (IU/ml)	Erosive	Disease activity	Current therapy	Cells /nl synovial fluid
11335	78	female	100	340	yes	moderate	Prednisone 10mg/d	23,25
11296	31	female	218	1184	n.d.	high	No DMARDs	10,65
8777	45	female	69	1723	yes	High	Prednisone 10mg/d Abatacept 125mg every 3 weeks	13,5
7815	88	female	8,9	2769	yes	high	Etanercept 50mg/week	<0,2
6735	65	female	287	154,7	yes	moderate	No DMARDs	5
3769	69	female	900	neg.	yes	moderate	Adalimumab	8,75
2163	60	female	neg.	1965	yes	moderate	No DMARDs,	4,05

							Piroxicam	
984,8	74	male	197	n.d.	yes	moderate	Prednisone 6,5mg/d	1
444	77	female	90	159	yes	moderate	Methotrexate 12,5mg s.c./week Prednisone 6mg/d	1,6
442,8	86	male	59,1	86	yes	moderate	Prednisone 10mg/d	1,15
110	50	female	neg.	neg.	no	moderate	Prednisone 4mg/d Etanercept	14

Suppl. Table 2. Characteristics of the RA patients whose synovial fluid samples were analyzed.

The table refers to figure 3. Values represent absolute numbers. Abbreviations: DMARDs=disease-modifying anti-rheumatic drugs, JAK=janus kinase, SF=synovial fluid, n.d.= not determined. Of note, 2 patients (36 year-old and 66 year-old females) were punctured twice.

<i>CD16</i> <i>Activation</i> <i>Index</i>	Age	Gender	Diagnosis	Erosive	Disease activity	Current therapy	Cells /nl synovia l fluid
3299	36	female	Juvenile idiopathic arthritis HLA-B27+ ANA+	nd	moderate	Adalimumab Sulfasalazine Prednisone	4,5
1218	36	female	Juvenile idiopathic arthritis HLA-B27+ ANA+	nd	moderate	Adalimumab Sulfasalazine Prednisone	4,6
498,8	57	female	Psoriatic arthritis	no	moderate	Prednisone 8mg/d	9,05
433,8	55	male	Seronegative RA with secondary AA amyloidosis, but current effusion due to episode of gout with abundant	yes	remissio n of RA, active gout	Tocilizumab 162 mg s.c./week Prednisone 15 mg/day	9,9

			crystals in sample				
298,5	53	female	Activated Osteoarthritis	no	moderate	Prednisone	0,15
281,8	79	female	RF+ ACPA+ RA, but current effusion due to osteoarthritis with indication for endoprothetic replacement (knee)	yes	moderate	Abatacept	0,16
257,7	48	female	HLA-B27+ peripheral Spondylarthritis	nd	moderate	Methotrexate 15mg sc/week	0
173,4	66	female	1. Activated Osteoarthritis 2. Polymyositis	nd	moderate	Azathioprine 125mg/d	0,27
126,9	66	female	1. Activated Osteoarthritis 2. Polymyositis	nd	moderate	Azathioprine 125mg/d	0,29
115,5	73	male	Polymyalgia rheumatica	nd	moderate	Leflunomide 20mg Prednisone 4mg	1,25
79,04	56	male	Unclear joint swelling	yes	moderate	Prednisone 10mg Anakinra Leflunomide 10mg	1
61,37	49	male	Psoriatic arthritis	nd	high	Methotrexate 15mg sc/week	5,8
40,54	60	male	Psoriatic arthritis	yes	moderate	No immunosuppressive therapy	0,5
40,42	37	male	Chlamydia trachomatis-associated reactive arthritis	nd	moderate	Prednisone 40mg/d	3,3
27,73	46	female	Immune related adverse event arthritis	nd	high	PD-L1 inhibitor	16,15

Suppl. Table 3. Characteristics of the non-RA patients whose synovial fluid samples were analyzed.

The table refers to figure 3. Values represent absolute numbers. Abbreviations: DMARDs=disease-modifying anti-rheumatic drugs, JAK=janus kinase, SF=synovial fluid, nd= not determined. Of note, 2 patients (36 year-old and 66 year-old females) were punctured twice.